NEW YORK (GenomeWeb) – Wafergen Biosystems today said that it has raised $15.7 million in net proceeds from a public offering. 

The firm issued a total of 6,170,000 shares of common stock, shares of preferred stock convertible into approximately 11,080,000 shares of common stock, and warrants to purchase 17,250,000 shares of common stock. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.